Baudax Bio, Inc. (BXRX)
| Market Cap | 959.05K |
| Revenue (ttm) | 326,000 |
| Net Income (ttm) | -7.15M |
| Shares Out | 43.59M |
| EPS (ttm) | -2.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,076,219 |
| Open | 0.0280 |
| Previous Close | 0.0273 |
| Day's Range | 0.0200 - 0.0285 |
| 52-Week Range | 0.0137 - 6.8900 |
| Beta | 1.63 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 28, 2023 |
About BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB revers... [Read more]
Financial Performance
In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.
Financial StatementsNews
Baudax Bio Announces Corporate Update
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utiliz...
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utiliz...
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizi...
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human...
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modes...
Baudax Bio shares jump on acquisition of TeraImmune
Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune...
Baudax Bio Acquires TeraImmune, Inc.
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 Secondary Efficacy Analyses, Including of Neuromuscular...
Baudax Bio Announces Date of Reconvened Annual Meeting
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently an...
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio...
Baudax Bio to Present at the Sidoti Virtual Investor Conference
MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announce...
Baudax Bio Announces Closing of $4 Million Public Offering
MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related setting...
Baudax Bio Announces Pricing of $4 Million Public Offering
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related setti...
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
MALVERN, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announ...
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
Company Focuses on Development of Neuromuscular Blocking Agents
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20...
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful...
Baudax's stock rallies after announcing start to Phase 2 clinical trial
Shares of Baudax Bio Inc. BXRX, +20.77% soared 62.6% in premarket trading on Friday, the day after the company said it started a Phase 2 clinical trial evaluating an experimental treatment for neuromu...
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation...
Baudax Bio Announces Closing of $5 Million Public Offering
MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settin...
Baudax Bio Announces Pricing of $5 Million Public Offering
MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today annou...
Baudax Bio Announces 1-for-40 Reverse Stock Split
MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Compa...
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
BX 1000 Phase II Trial Underway
Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock
MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings, today...